One in fifty-nine children will be diagnosed with autism, the emotional and economic burden of autism is very high and it has a ripple effect: it effects the individual with ASD, their family, community and society in general.
SensPD strives to become the main screening test for Autism right after birth, hence early interventions will be available and the lives of those children will change dramatically for the best. SensPD is not the story of one in fifty-nine but the story of all of every one of us. As parents, we all want the best for our children and SensPD provides that hope.
Our mission at SensPD is to make sure that all newborns are properly tested and no family has to deal with the fear and worry of late autism detection ever again.
SensPD was founded with a solid team with a proven business track record, coupled with the strong support of the scientific community.
Over 8 years of experience in key positions in international business development, management and building companies (start-ups & starting companies)
Raphael (Raffi) Rembrand
Founder & Head of Research
Chemical engineer with over 40 years of experience in signal processing. An independent researcher in the field of autism for the last 18 years.
Dr. Einat Zisman PhD MBA
Chairperson of the Board
Over 20 years experience in medical projects. Founded and managed FuturX Biotechnology Incubator, managed Hadasit Medical Research Services and Development Ltd., and served as VP Business Development at Yeda, the technology commercialization arm of the Weizmann Institute of Science
Prof. Itamar Shalit, M.D., MPA
Prof. Shalit is an Associate Professor in Pediatrics, Sackler Faculty of Medicine, Tel-Aviv University and a world authority in Pediatric Infectious Diseases. Author of more than 90 peer reviewed scientific papers and currently serves as the CEO of the Galilee Biomedical Research Administration.